Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAetna Hepatitis A Vaccine Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0048

    Hepatitis A Vaccine

    Customize your policy alerts

    Sign up for Aetna Policy 0048 alerts

    Get alerted when Policy 0048 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, coverage limitations, and coding guidance for hepatitis A vaccination and post-exposure prophylaxis for members in alignment with ACIP/AAP recommendations.

    Policy Summary
    PayerAetna
    PolicyHepatitis A Vaccine
    Policy CodePolicy 0048
    Change TypeAdministrative review — no material clinical changes
    Effective DateAug 3, 1995
    Last ReviewMar 17, 2023
    Next Review DateJan 11, 2024
    Key ActionInitiate HepA vaccine within 2 weeks after hepatitis A exposure for post-exposure prophylaxis when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12+At-risk groups listed
    2 weeksPEP initiation window
    2-doseStandard single-antigen schedule
    3/4-doseTwinrix schedules
    03/17/2023Last review
    01/11/2024Next review

    Coverage Criteria for Hepatitis A Vaccine

    Routine and Risk-based Vaccination Criteria

    Covered when ANY of the following risk-based or exposure conditions are met (per ACIP/AAP):

    Routine childhood: All children 12 to 23 months of age
    Catch-up pediatric/adolescent: Children and adolescents aged 2–18 years who have not previously received HepA vaccine
    HCT recipients: Hematopoietic cell transplant (HCT) recipients may be vaccinated or revaccinated routinely after HCT regardless of stem cell source
    Homeless: Individuals aged 1 year and older who are homeless
    HIV infection: Individuals aged 1 year and older who have HIV infection regardless of immune suppression level
    Household contact of international adoptee: Individuals anticipating close personal contact with an international adoptee from a country with high or intermediate endemicity during the first 60 days after arrival
    Chronic liver disease: Individuals with chronic liver disease (including HBV, HCV, cirrhosis, fatty liver, alcoholic liver disease, autoimmune hepatitis) or persistently elevated ALT/AST >2x ULN>2x ULN
    Occupational risk: Individuals with occupational risk for HAV exposure (e.g., primate handlers, research laboratory personnel working with HAV-containing material)
    Injection drug use: Injection and illicit drug users
    International travelers to areas where hepatitis A is endemic (including tourists, military personnel, missionaries, immigrants returning to visit)
    MSM: Men who have sex with men (MSM)
    Pregnant at-risk: Pregnant women identified to be at risk for HAV infection during pregnancy or at risk for severe outcome
    Adults in high-risk settings: Unvaccinated adults ≥19 years in settings with HAV risk factors (group homes, homeless shelters, syringe services, nonresidential day care for developmental disabilities)

    Post-Exposure Prophylaxis

    Post-exposure prophylaxis (PEP) coverage criteria:

    PEP timing: Initiate HepA vaccine within 2 weeks after hepatitis A exposure for prophylaxis<=2 weeks
    PEP agent by age/condition: For healthy persons 12 months–40 years, single-antigen HepA vaccine is preferred to immune globulin; persons >40 years, immunocompromised, chronic liver disease, infants <12 months, or allergic to vaccine should receive immune globulin (or both in certain immunocompromised/chronic liver disease exposures)

    Covered Indications (ACIP)

    Covered when ANY of the following ACIP-recommended indications apply

    ACIP-recommended indication list: Includes: international travelers to high/intermediate endemic countries; men who have sex with men; persons who use injection or noninjection drugs; persons with occupational risk (working with infected nonhuman primates or HAV-containing material); persons anticipating close personal contact with an international adoptee (first 60 days); persons experiencing homelessness; persons with HIV infection; persons with chronic liver disease; persons living in group settings for developmental disabilities; persons who are incarcerated; older adults (>40 years) at higher risk of severe disease; all children aged 12–23 months and catch-up vaccination for children/adolescents 2–18 years who are unvaccinated; pregnant women at risk; vaccination during outbreaks for at-risk groups; persons in settings serving high proportions of at-risk persons

    Postexposure Prophylaxis

    PEP and special circumstances

    PEP guidance: HepA vaccine is recommended for PEP for persons aged ≥12 months; adults >40 years may receive immune globulin if indicated; immunocompromised persons or those with chronic liver disease exposed within the past 14 days who have not completed the 2-dose series should receive both immune globulin (0.1 mL/kg) and HepA vaccine administered simultaneously at separate anatomic sites; the second vaccine dose for long-term immunity should be given ≥6 months after the first dose but is not required for PEP14 days

    Travel-related Vaccination

    Travel and age-specific recommendations

    Travel dose and infant guidance: Administer HepA to infants aged 6–11 months traveling internationally; this dose does not count toward the routine series. Healthy persons aged 12 months–40 years planning travel to high/intermediate endemic areas who are unvaccinated should receive a single dose as soon as travel is considered and complete series later. Persons >40 years, immunocompromised, or with chronic liver disease planning travel should receive a single dose as soon as travel is considered.6–11 months

    Immunocompromised / Transplant Candidates

    Immunocompromised and transplant considerations

    HCT and solid organ transplant guidance: HCT recipients who received vaccines before HCT should be revaccinated after HCT; revaccination doses of HepA are recommended. Solid organ transplant candidates who are unvaccinated, undervaccinated, or seronegative for hepatitis A — particularly liver transplant candidates aged 12–23 months and ≥2 years — should receive a HepA vaccine series.

    Schedule Effectiveness and Durability

    Evidence on schedule effectiveness

    One vs two dose program evidence: 2-dose universal vaccination programs show rapid declines in hepatitis A incidence and high vaccine effectiveness (≈95%+ over 3–5 years) with antibody persistence documented up to 15 years. Evidence for 1-dose programs is more limited, with documented antibody persistence up to 10 years in some studies.

    Most Aetna HMO plans exclude coverage of immunizations that are required solely for travel or work. Before providing or billing for hepatitis A vaccination for travel- or employment-related reasons, verify the member’s benefit plan description to confirm whether that immunization is covered under their specific plan.

    Vaccination of persons who receive blood products for clotting disorders (for example, hemophilia) is no longer routinely recommended because modern recombinant clotting factor concentrates are treated to eliminate HAV contamination; the risk of HAV transmission in this population is now considered similar to the general population.

    Certain occupational or setting-based groups—such as food handlers, child care centers, schools, and health care personnel—are generally considered low risk for hepatitis A transmission and are not routinely indicated for HepA vaccination solely because of those roles. Routine childhood vaccination and community risk factors drive most prevention efforts rather than routine occupational immunization for these groups.

    Although this policy includes persons with chronic liver disease (including hepatitis C virus infection) among groups for whom HepA vaccination is recommended, published analyses have questioned the cost-effectiveness of routine HAV vaccination for all persons with HCV. One meta-analysis estimated a very large number needed to vaccinate and high cost per death prevented, concluding that routine universal vaccination of all HCV-infected persons may not be cost-effective; clinical judgment and benefit considerations should inform decisions for individual members.

    Coding and Billing Codes

    Covered CPT Codes (if criteria met)CPTCovered
    90632Hepatitis A vaccine (Hep A), adult dosage, for intramuscular use.
    90633Hepatitis A vaccine (Hep A), pediatric/adolescent dosage-2 dose schedule, for intramuscular use.
    90634Hepatitis A vaccine (Hep A), pediatric/adolescent dosage-3 dose schedule, for intramuscular use.
    90636Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use.
    Related CPT/HCPCS Codesmixed
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
    38241Hematopoietic progenitor cell (HPC); autologous transplantation.
    84450Transferase; aspartate amino (AST) (SGOT).
    84466Transferase; alanine amino (ALT) (SGPT).
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency services, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    ICD-10 Codes (covered if criteria met / relevant diagnoses)ICD-10
    B15.0-B15.9Acute hepatitis A.
    B16.0-B16.9Acute hepatitis B.
    B17.0Acute delta-(super) infection of hepatitis B carrier.
    B17.10Acute hepatitis C without hepatic coma.
    B17.11Acute hepatitis C with hepatic coma.
    B18.0Chronic viral hepatitis B with delta-agent.
    B18.1Chronic viral hepatitis B without delta-agent.
    B18.2Chronic viral hepatitis C.
    B19.1Unspecified viral hepatitis B.
    B19.20Unspecified viral hepatitis C without hepatic coma.
    1–10 of 28
    1/3

    Provider Actions, Prior Authorization, and Documentation

    Billing Rule

    Codes clinicians may need to reference for authorization

    Codes clinicians may need to reference for authorization and billing include covered HepA vaccine CPT codes and related ICD-10/HCPCS codes. Examples in this bulletin include: 90632, 90633, 90634, 90636 (HepA and HepA-HepB vaccine codes); ICD-10 codes for hepatitis, HIV, exposure, homelessness and encounter for immunization (e.g., B15.*-B19.*, B20, Z20.828, Z23, Z59.00-Z59.02, Z94.*); and related CPT/HCPCS listed in the bulletin. Verify coverage and prior-authorization requirements with the member’s benefit plan.

    • Select CPT/HCPCS/ICD-10 codes from the Clinical Policy Bulletin when submitting authorization or claims.
    • Common vaccine CPT codes: 90632, 90633, 90634, 90636.
    • Use ICD-10 codes indicating exposure, risk factor, or encounter for immunization (e.g., Z20.828, Z23) when applicable.
    Note

    Clinical Policy Bulletins constitute neither offers of coverage nor medical advice

    Background and Evidence Summary

    Hepatitis A vaccine is approved for persons aged 12 months and older and is typically administered as a 2-dose single-antigen series with doses separated by at least 6 months. The combined hepatitis A–hepatitis B vaccine (Twinrix) is licensed for adults ≥18 years and is provided as a standard 3-dose schedule (0, 1, and 6 months) or an accelerated 4-dose schedule (0, 7, 21–30 days with a booster at 12 months) when rapid protection is needed.

    Schedule Effectiveness and Durability — Evidence on effectiveness and durability (VE, antibody persistence)

    Evidence on schedule effectiveness

    VE and antibody persistence: Systematic review data: 2-dose programs demonstrated vaccine effectiveness ≥95% over 3–5 years and antibody persistence up to 15 years; 1-dose programs had more limited long-term data (antibody persistence up to 10 years in some studies). Ongoing epidemiologic monitoring is recommended for 1-dose programs.

    Definitions and Schedule Notes

    Twinrix (HepA-HepB) — Combination vaccine licensing and adult dosing schedules (3-dose or accelerated 4-dose).
    Product and indicationTwinrix (combined HepA-HepB) licensed for adults aged ≥18 years.
    Standard adult schedule3-dose schedule at 0, 1, and 6 months.
    Accelerated schedule4-dose accelerated schedule: doses at 0, 7, and 21–30 days, with a booster at 12 months; first 3 doses of the 4-dose schedule provide protection equivalent to first 2 doses of standard schedule.
    Antigen contentContains 720 ELISA units of HAV antigen (half of Havrix adult dose) plus 20 μg recombinant HBV surface antigen.
    Use case for accelerated scheduleUseful if travel or potential exposure is expected before the 2nd dose (1 month) on the original schedule.
    Standard HepA series — Two-dose single-antigen hepatitis A vaccine schedule with doses separated by at least 6 months.

    Policy Dates and Revision History

    1995-08-03effective_date

    Policy originally became effective on August 3, 1995.

    2023-03-17last_review

    Clinical policy last reviewed on March 17, 2023.

    2024-01-11next_review_scheduledLatest

    Next scheduled policy review on January 11, 2024.

    Policy Summary
    PayerAetna
    PolicyHepatitis A Vaccine
    Policy CodePolicy 0048
    Change TypeAdministrative review — no material clinical changes
    Effective DateAug 3, 1995
    Last ReviewMar 17, 2023
    Next Review DateJan 11, 2024
    Key ActionInitiate HepA vaccine within 2 weeks after hepatitis A exposure for post-exposure prophylaxis when criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Hepatitis A VaccineCoding and Billing CodesProvider Actions, Prior Authorization, and DocumentationBackground and Evidence SummaryDefinitions and Schedule NotesPolicy Dates and Revision History

    Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. They contain only a partial, general description of plan or program benefits and do not constitute a contract. Providers should not treat the bulletin as a guarantee of payment and must verify member-specific benefits and any plan-level exclusions (for example, many Aetna HMO plans exclude travel- or work-required immunizations).

    • Clinical Policy Bulletins do not guarantee coverage or payment.
    • Participating providers are independent contractors and are responsible for medical advice and treatment.
    • Check the member’s benefit plan description for exclusions or requirements before billing.
    Documentation Required

    Coding and documentation guidance

    Coding and documentation guidance: document the member’s exposure status, risk factors (if disclosed), indication for vaccination or PEP, and the vaccine product and dose administered. Use appropriate ICD-10 codes for exposure, encounter for immunization, homelessness, occupational exposure, chronic liver disease, or HIV as applicable. Ensure CPT/HCPCS vaccine administration and vaccine product codes match the service provided.

    • Document indication (e.g., post-exposure prophylaxis, travel, occupational risk, homelessness).
    • Include vaccine product and dose (e.g., 90632, 90633, 90634, 90636) and administration details in the medical record.
    • Use ICD-10 codes for exposure or risk where applicable (examples: Z20.828, Z23).
    Documentation Required

    No additional documentation requirements specified in the bulletin

    No specific documentation requirements are stated in this Clinical Policy Bulletin beyond standard medical record documentation; however, providers should retain records supporting the medical necessity and indication for vaccination and any authorization submitted.

    • The bulletin does not list additional document submission requirements for HepA vaccine.
    • Maintain medical record documentation of exposure, risk factors, consent, vaccine product, dose, lot, and administration site.
    Documentation Required

    Documentation and provider responsibility

    Documentation and provider responsibility: treating providers are solely responsible for medical advice and treatment. Providers must verify member eligibility and benefits, confirm any prior-authorization requirements with Aetna or the member’s plan, and follow ACIP guidance for indications and PEP recommendations.

    • Verify member eligibility and benefit coverage before delivering and billing for vaccine.
    • Confirm any prior-authorization or plan exclusions that may affect coverage (e.g., travel/work-related vaccines).
    • Follow ACIP guidance and document clinical rationale for vaccine versus immune globulin when applicable.
    Note

    PEP preference guidance (vaccine vs immune globulin)

    Post-exposure prophylaxis (PEP) preference guidance: ACIP recommends single-antigen hepatitis A vaccine for healthy persons aged 12 months to 40 years as preferred PEP when initiated within 2 weeks after exposure; immune globulin is preferred for persons >40 years and for infants <12 months, immunocompromised persons, those with chronic liver disease, or those allergic to vaccine components. Consider vaccine if immune globulin is unavailable and weigh exposure risk when deciding for persons >40 years.

    • For healthy persons 12 months–40 years: vaccine preferred for PEP within 2 weeks of exposure.
    • For >40 years, <12 months, immunocompromised, chronic liver disease, or vaccine allergy: immune globulin preferred.
    • If immune globulin unavailable, vaccine may be used after clinical consideration.
    Step Therapy

    Step therapy not described

    No step therapy requirements or sequencing are described in this Clinical Policy Bulletin for hepatitis A vaccination.

    • No step therapy or prior-treatment requirements specified for HepA vaccine in this bulletin.
    Routine seriesTwo-dose single-antigen hepatitis A vaccine series for persons aged ≥12 months.
    Minimum intervalDoses should be separated by at least 6 months (recommended intervals: Vaqta 6–18 months; Havrix 6–12 months).
    Preferred product consistencyEither vaccine (Havrix or Vaqta) can be used for either dose, but using the same vaccine for both doses is preferable.
    Formulations by ageVaqta: 25 units (age 12 months–18 years) or 50 units (≥19 years). Havrix: 720 ELISA units (12 months–18 years) or 1,440 ELISA units (≥19 years).
    Postexposure prophylaxis (PEP) — Use of HepA vaccine for persons aged ≥12 months after exposure; IG use for older adults or special cases.
    Eligible age for PEPHepA vaccine is recommended for postexposure prophylaxis for persons aged ≥12 months.
    Timing windowInitiate HepA vaccine within 14 days (2 weeks) after hepatitis A exposure for prophylaxis.
    Use of immune globulin (IG)IG may be administered to adults >40 years if indicated; immunocompromised persons or those with chronic liver disease exposed within 14 days who have not completed a 2-dose series should receive both IG (0.1 mL/kg) and HepA vaccine simultaneously at separate anatomic sites.
    Infant considerationsMMR and HepA simultaneous administration is recommended for infants aged 6–11 months traveling internationally; infants <12 months are candidates for IG in certain PEP scenarios.
    Routine vaccination schedules — Routine HepA vaccination is a 2-dose schedule; combined HepA-HepB follows a 3-dose schedule; travel-related dosing notes.
    Routine childhood scheduleRoutine HepA vaccination: 2-dose series for all children aged 12–23 months.
    Combined HepA-HepB scheduleWhen using combined HepA-HepB (Twinrix) in adults, follow a 3-dose schedule (0, 1, 6 months) or accelerated 4-dose schedule as needed.
    Travel-related dosing noteAdminister HepA to infants aged 6–11 months traveling internationally; this travel-related dose does not count toward the routine 2-dose series.
    Catch-up and travel single-dose guidanceUnvaccinated healthy persons aged 12 months–40 years planning travel to high/intermediate endemic areas should receive a single dose as soon as travel is considered and complete the series later; persons >40 years or with immunocompromising conditions or chronic liver disease should also receive a single dose as soon as travel is considered.